SQ Innovation today announced topline results from the SUBCUT HF II trial of its product Lasix® ONYU, a novel subcutaneous formulation of furosemide for people with heart failure-associated edema.
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...
Malaria control and elimination is threatened by the spread of insecticide resistance and behavioral adaptation of vectors. Whether mass administration of ivermectin, a broad-spectrum antiparasitic ...
Results of a multisite randomized trial of Bright IDEAS-Young Adults: Efficacy of problem-solving skills training on distress and health-related quality of life. This is an ASCO Meeting Abstract from ...
Total hip arthroplasty leads to the best outcomes in the treatment of moderate-to-severe hip osteoarthritis, according to a ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
CoreTissue BioEngineering Inc. ("CTBE"), a medical device start-up (Headquarters: Yokohama City, Kanagawa Prefecture, CEO: Yoji Jokura, Ph.D.) announces that the safety evaluation in the safety cohort ...
In recent book, UChicago’s Nicole P. Marwell and Jennifer E. Mosley argue that the research method isn’t always the best tool ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results